Advanced MR Imaging of Osteoarthritis
Launched by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST · Aug 25, 2016
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Group 1 Inclusion Criteria:
- • Meets American College of Rheumatology (ACR) criteria for OA
- • Kellgren-Lawrence grade 2-3 OA on knee radiograph
- • Medial compartment predominant disease
- • Neutral alignment
- • Aged 40-60
- • Body Mass Index (BMI) \< 35 kg per square meter
- • Ambulatory and in good general health
- Group 2 Inclusion Criteria:
- • No current symptoms of knee pain or stiffness or other clinical features of OA
- • Aged 40-60
- • BMI \< 35 kg per square meter
- • Ambulatory and in good general health
- Exclusion Criteria (both groups):
- • History of ipsilateral lower limb fracture
- • History of ipsilateral lower limb surgery (including arthroscopy)
- • Metabolic bone disease
- • Inflammatory arthritis
- • Haematological malignancy
- • Paget's disease
- • Bone metastases
- • Contraindication to MR imaging (e.g. pacemaker, severe claustrophobia)
- • Contraindication to intravenous gadolinium based contrast medium administration (see 'Ethical Considerations' section)
- • Unable to consent
About Cambridge University Hospitals Nhs Foundation Trust
Cambridge University Hospitals NHS Foundation Trust is a leading healthcare organization in the UK, dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent academic health science center, it integrates cutting-edge research with clinical practice, fostering collaboration between healthcare professionals, researchers, and patients. The Trust is committed to delivering high-quality, evidence-based healthcare while actively participating in the development of new therapies and interventions aimed at enhancing health outcomes. With a focus on excellence in clinical research, Cambridge University Hospitals aims to translate scientific discoveries into effective treatments, ultimately benefiting the wider community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cambridge, Cambridgeshire, United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials